Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma

NCT01558869 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Adenocarcinoma

Interventions

DRUG: Capecitabine
DRUG: Oxaliplatin
DRUG: Irinotecan

Sponsor

The University of Hong Kong